首頁 > 市場調查報告書 > 製藥

消化器

急性胰臟炎市場規模、佔有率和成長分析（按診斷、病因、治療、最終用戶和地區分類）—產業預測，2026-2033年

市場調查報告書

商品編碼

1895587

急性胰臟炎市場規模、佔有率和成長分析（按診斷、病因、治療、最終用戶和地區分類）—產業預測，2026-2033年

Acute Pancreatitis Market Size, Share, and Growth Analysis, By Diagnosis (Imaging Tests, Laboratory Tests), By Cause (Gallstones, Alcohol), By Treatment, By End user, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月15日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球急性胰臟炎市場規模將達到 61.4 億美元，到 2025 年將達到 65 億美元，到 2033 年將達到 102.9 億美元，在預測期（2026-2033 年）內，複合年成長率為 5.9%。

全球急性胰臟炎市場涵蓋了這種以急性胰臟發炎為特徵的嚴重的診斷、治療和管理。推動市場成長的因素包括急性胰臟炎盛行率的上升、診斷技術的進步以及創新治療方法的湧現。肥胖、飲酒、膽結石和某些藥物等風險因素的增加，進一步加劇了該疾病在全球的發生率。在這個競爭激烈的市場中，眾多製藥公司、醫療設備製造商和醫療保健服務提供者正在開發和推廣尖端解決方案。主要企業正專注於臨床試驗、建立合作夥伴關係和策略合作，以擴大產品和服務範圍並鞏固市場地位。這個充滿活力的市場旨在提供有效的護理解決方案，以應對與急性胰臟炎相關的複雜挑戰。

全球急性胰臟炎市場成長要素

由於多種相互關聯的因素，全球急性胰臟炎市場預計將迎來顯著成長。糖尿病患者數量的顯著增加預計將是推動市場成長的重要因素，因為胰臟炎會損害胰臟中產生胰島素的細胞，從而增加患者罹患糖尿病的風險。此外，人口老化以及政府為提高公眾對胰臟炎的認知而採取的主導，預計也將推動市場需求。消費者生活方式的改變和政府的支持性政策也將對市場擴張起到關鍵作用。此外，肥胖症和胰臟癌發病率的上升預計也將進一步加速市場成長。

全球急性胰臟炎市場阻礙因素

由於面臨許多重大挑戰，全球急性胰臟炎市場預計將成長緩慢。治療費用不斷上漲嚴重阻礙了患者獲得治療的機會，尤其是在醫療資源有限的發展中地區。此外，嚴格的法規環境也使得新治療方法和新技術的引入更加複雜，進一步限制了市場擴張。同時，報銷體係不完善以及公眾對該疾病的認知度較低也是阻礙因素。這些因素綜合起來，可能會阻礙市場發展，並限制急性胰臟炎治療領域的成長機會。

全球急性胰臟炎市場趨勢

全球急性胰臟炎市場正經歷著變革性的趨勢，其核心在於透過各種創新策略改善患者預後。目前，醫療產業正大力推動早期診斷和早期療育，醫療專業人員優先使用先進的診斷工具，以便在適當的時機啟動治療。此外，個人化醫療的興起正在改變治療格局，其驅動力是基因分析和分子診斷技術，這些技術能夠根據每位患者的個別特徵量身定做治療方案。這一趨勢促進了針對急性胰臟炎獨特基因突變的標靶治療的研發。同時，數位醫療解決方案和微創介入治療的整合也日益增強，這些措施共同旨在簡化患者管理流程並提高康復率。總而言之，這些市場趨勢反映了醫療產業致力於提升急性胰臟炎治療品質的決心。

Pfizer Inc.（United States）
Merck & Co., Inc.（United States）
Baxter International Inc.（United States）
Abbott Laboratories（United States）
B. Braun SE（Germany）
CalciMedica Inc.（United States）
Dynavax Technologies Corporation（United States）
Fresenius SE & Co. KGaA（Germany）
GlaxoSmithKline plc（United Kingdom）
Olympus Corporation（Japan）
SCM Lifescience（South Korea）
Samsung Bioepis（South Korea）
GNT Pharma Co.（South Korea）
Medtronic plc（Ireland）
Boston Scientific Corporation（United States）
Takeda Pharmaceuticals（Japan）
Novartis AG（Switzerland）
AbbVie Inc.（United States）
General Electric Company（United States）
Mitsubishi Tanabe Pharma Corporation（Japan）

結論與建議

簡介目錄

Product Code: SQMIG35D2197

Global Acute Pancreatitis Market size was valued at USD 6.14 Billion in 2024 and is poised to grow from USD 6.5 Billion in 2025 to USD 10.29 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The global acute pancreatitis market encompasses the landscape surrounding the diagnosis, treatment, and management of this severe condition characterized by sudden pancreatic inflammation. Several factors stimulate market growth, including the rising prevalence of acute pancreatitis, advancements in diagnostic methodologies, and the emergence of innovative treatment alternatives. Heightened risk factors such as obesity, alcohol use, gallstones, and certain medications further exacerbate the condition's incidence worldwide. The market is notably competitive, with numerous pharmaceutical companies, medical device manufacturers, and healthcare providers engaged in the development and commercialization of cutting-edge solutions. Key players are focusing on clinical trials, partnerships, and strategic collaborations to expand their offerings and enhance market position. This dynamic market aims to provide effective care solutions to address the complexities associated with acute pancreatitis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Pancreatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Pancreatitis Market Segments Analysis

Global Acute Pancreatitis Market is segmented by Diagnosis, Cause, Treatment, End user and region. Based on Diagnosis, the market is segmented into Imaging Tests and Laboratory Tests. Based on Cause, the market is segmented into Gallstones, Alcohol and Others. Based on Treatment, the market is segmented into Intravenous fluid, Nutritional support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is poised for significant growth due to several interrelated factors. A notable rise in diabetes cases is expected to contribute, as pancreatitis can impair insulin-producing cells in the pancreas, leading to increased diabetes risk among affected individuals. Furthermore, an aging population coupled with heightened government initiatives aimed at raising awareness about pancreatitis is likely to bolster market demand. The influence of evolving consumer lifestyles, along with supportive government policies, will also play a pivotal role in market expansion. Additionally, the rising prevalence of obesity and pancreatic cancer will further propel the market's growth trajectory.

Restraints in the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is expected to experience sluggish growth due to a range of significant challenges. High treatment costs significantly hinder accessibility, particularly in developing regions where healthcare facilities may be limited. Furthermore, a stringent regulatory landscape complicates the introduction of new therapies and technologies, creating additional barriers to market expansion. Additionally, inadequate reimbursement practices and a general lack of public awareness about the condition further contribute to the constraints faced by the industry. Together, these factors are likely to impede the market's development and limit opportunities for growth in the treatment of acute pancreatitis.

Market Trends of the Global Acute Pancreatitis Market

The global acute pancreatitis market is witnessing transformative trends that focus on enhancing patient outcomes through various innovative strategies. A significant shift towards early diagnosis and intervention is emerging, with healthcare professionals emphasizing advanced diagnostic tools to facilitate timely treatment initiation. Additionally, the rise of personalized medicine is reshaping the therapeutic landscape, driven by genetic insights and molecular diagnostics that cater to individual patient profiles. This trend is fostering the development of targeted therapies designed to address the unique variations in acute pancreatitis. Complementing these approaches, there is an increasing integration of digital health solutions and minimally invasive interventions, collectively aiming to streamline patient management and improve recovery rates. Overall, these market trends reflect a commitment to advancing the quality of care in acute pancreatitis treatment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Acute Pancreatitis Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Imaging Tests
Laboratory Tests

Global Acute Pancreatitis Market Size by Cause & CAGR (2026-2033)

Market Overview
Gallstones
Alcohol
Others

Global Acute Pancreatitis Market Size by Treatment & CAGR (2026-2033)

Market Overview
Intravenous fluid
Nutritional support
Analgesics
Endoscopic Retrograde Cholangiopancreatography (ERCP)
Others

Global Acute Pancreatitis Market Size by End user & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Diagnostic Centers
Others

Global Acute Pancreatitis Market Size & CAGR (2026-2033)

North America (Diagnosis, Cause, Treatment, End user)
- US
- Canada
Europe (Diagnosis, Cause, Treatment, End user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Diagnosis, Cause, Treatment, End user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Diagnosis, Cause, Treatment, End user)
- Brazil
- Rest of Latin America
Middle East & Africa (Diagnosis, Cause, Treatment, End user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CalciMedica Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SCM Lifescience (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Bioepis (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GNT Pharma Co. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceuticals (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
General Electric Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitsubishi Tanabe Pharma Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments